Edwards Lifesciences Corporation (NYSE:EW) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been assigned an average rating of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $96.1364.

Several analysts have commented on the stock. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research report on Monday, November 3rd. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. BTIG Research restated a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (down previously from $108.00) on shares of Edwards Lifesciences in a report on Wednesday.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Analyst upgrades and reiterated buys lift longer‑term outlook — Wells Fargo raised its price target to $100 and moved to “overweight,” while BTIG and several other firms reiterated Buy ratings with ~$103 targets, supporting upside expectations. Article Title
• Positive Sentiment: Strong revenue growth and TAVR momentum highlighted on the earnings call — Management emphasized sustained Transcatheter Aortic Valve Replacement (TAVR) and other structural‑heart growth drivers; the company is leaning into growth after the quarter. Article Title
• Positive Sentiment: Options/contrarian take: some traders see the post‑earnings weakness as a buying opportunity — commentary suggests cleared uncertainty after results could support a tactical bullish trade. Article Title
• Neutral Sentiment: Mixed earnings print — Q4 revenue topped expectations and grew year‑over‑year, but EPS missed estimates. Revenue strength supports the growth narrative, while the EPS shortfall creates near‑term uncertainty. Article Title
• Neutral Sentiment: Sector context — Comparative coverage of healthcare earnings (AstraZeneca vs. Edwards vs. Zimmer Biomet) highlights macro/peer performance but is not specific to EW’s fundamentals. Article Title
• Negative Sentiment: Shareholder‑rights notice from Halper Sadeh LLC adds legal/uncertainty risk — a public call encouraging shareholders to contact the firm can prompt selling or increase perceived governance risk. Article Title

Edwards Lifesciences Stock Performance

NYSE:EW opened at $76.39 on Friday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm’s fifty day simple moving average is $83.55 and its 200 day simple moving average is $81.10. The stock has a market cap of $44.33 billion, a P/E ratio of 41.74, a price-to-earnings-growth ratio of 3.03 and a beta of 0.94. Edwards Lifesciences has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the sale, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. The trade was a 26.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,804 shares of company stock valued at $3,699,082 in the last three months. 1.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the third quarter worth $25,000. Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $28,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $28,000. Dorato Capital Management bought a new position in Edwards Lifesciences in the 4th quarter worth about $29,000. Finally, Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at about $28,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.